Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Haemacure to get $5 million investment from Swiss Red Cross:

This article was originally published in Clinica

Executive Summary

Haemacure is negotiating the terms of a SwFr7 million ($4.7 million) investment from ZLB, the central laboratory of the Swiss Red Cross. The funds will be used to launch Hemaseal APR, the Montreal-based company's fibrin sealant, the first such product to receive FDA approval. The product is used to stop bleeding and seal wounds in surgical procedures involving cardiopulmonary bypass, colostomy closure and spleen injuries.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts